YL
Therapeutic Areas
Owkin Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AI Drug Discovery Pipeline | Oncology & other diseases | Discovery |
| OKN4395 | Oncology (Immunotherapy) | Pre-clinical |
| MSIntuit® CRC | Colorectal Cancer (MSI screening) | Approved |
| RlapsRisk® BC | Early Breast Cancer | Approved |
| Glioblastoma Moonshot | Glioblastoma | Research |
| K Pro | Drug Discovery & Development Platform | Commercial |
Leadership Team at Owkin
TC
Thomas Clozel
Co-founder and Chief Executive Officer
PW
Pascal Weinberger
Deputy Chief Executive Officer
ED
Eric Durand
Chief R & Tech Officer
AT
Andrea Tassistro
Chief Transformation Officer
GB
Graeme Bell
Chief Financial Officer
AT
Antonia Trower
Chief Marketing Officer
CH
Caroline Hoffmann
Chief Medical Officer
MT
Marie-Alice Tantardini
Chief People Officer
JP
Jean-Frédéric Petit-Nivard
Chief Commercial Officer
AH
Anna Huyghues-Despointes
Chief Corporate Dev & Ops Strategy Officer